News
Pharmacogenomics in 2026: From Research Concept to Clinical Workflow
Pharmacogenomics has moved well beyond the research phase. In 2026, healthcare systems are using genetic insights as part of routine prescribing decisions, especially in areas such as oncology, cardiology, psychiatry, and pain management. What once sat inside academic journals...
Business & Industry
Pfizer and Innovent Finalize $10.5 Billion Global Oncology Agreement
The Pfizer Innovent Cancer Deal has been finalized, establishing a global licensing and collaboration agreement valued at up to $10.5 billion. The transaction focuses on the research, development, and commercialization of 12 early-stage oncology programs. This arrangement combines the...
News
The Push for Greater Accuracy in Clinical Trials
Clinical trials are the foundation of modern medicine. Every treatment, therapy, and medical breakthrough relies on accurate research to ensure safety and effectiveness. However, maintaining accuracy across complex studies has always been a challenge. With large patient populations, multiple...
News
The Four Principles of Medicines Optimisation in Primary Care
Medicines optimisation in primary care became a formal discipline in 2013, when the Royal Pharmaceutical Society set out a four-principle framework that has guided the work ever since. The language was new at the time, but the underlying ideas...
Business & Industry
MSD and Adcendo Initiate Phase Ib Collaboration for Solid Tumours
MSD and Adcendo have established a collaboration and supply agreement to evaluate the combination of ADCE-T02 and pembrolizumab. The companies are preparing for a Phase Ib solid tumour clinical trial targeting patients with advanced solid tumours.
Adcendo will act as...
News
SK Bioscience Inks Colombia Vaccine Localization Deal
In a critical step for Colombia vaccine localization, SK Bioscience will execute a vaccine technology transfer with Colombia’s state-owned pharmaceutical enterprise, VECOL. The partnership focuses on building a local manufacturing site to align with the country's national vaccine localization...
Business & Industry
Eli Lilly Returns to Infectious Disease with $3.8 Billion Acquisition Strategy
After a seven-year absence from the sector, Eli Lilly is returning to the field through a trio of corporate purchases valued at more than $3.8 billion. This infectious disease M&A activity secures Curevo, LimmaTech Biologics, and Vaccine Company, firmly...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read